Retatrutide tops 28.7% weight loss

Obesity drugs are starting to look less like “diet shots” and more like broad metabolic medicines. That is the real story here. Lilly’s phase 3 TRIUMPH-4 trial says retatrutide did two hard things at once in people with obesity and knee osteoarthritis — it drove very large weight loss and it eased joint pain enough to hit both co-primary endpoints. The headline number was 28.7% average weight loss at 68 weeks on the 12 mg dose, plus a 75.8% drop in WOMAC pain scores. ### What exactly is retatrutide? Retatrutide is Lilly’s experimental once-weekly drug that hits three hormone pathways at once — GIP, GLP-1, and glucagon. That makes it different from semaglutide, which mainly targets GLP-1, and tirzepatide, which targets GIP and GLP-1. The bet is that the third lever can push weight loss further, though it also raises the bar on safety and tolerability. Lilly is still testing it across a big late-stage program, so this is not an approved medicine yet. (investor.lilly.com) ### Why is knee osteoarthritis the interesting test? Because this is where weight loss has to prove it does something people can actually feel. Obesity and knee osteoarthritis feed each other — more load on the joint, more pain, less movement, then often more weight gain. A drug that trims pounds but does not improve pain or function is useful. But a drug that helps people move again starts to look like something bigger. TRIUMPH-4 was built around that tougher standard. (investor.lilly.com) ### What did Lilly actually report? The trial enrolled adults with obesity or overweight plus knee osteoarthritis, and without diabetes. Over 68 weeks, people on retatrutide 12 mg lost an average 28.7% of body weight — about 71.2 pounds. Lilly also said WOMAC pain scores improved by up to 4.5 points, or 75.8%, and physical function improved significantly. More than 1 in 8 treated patients ended the trial completely free from knee pain. (investor.lilly.com) ### Is 28.7% a big deal? Yes — that is the number making everyone pay attention. Earlier phase 2 retatrutide data showed up to 24.2% mean weight reduction at 48 weeks, which was already striking. TRIUMPH-4 pushes the phase 3 figure higher and does it in a population with painful knee disease, not just a general obesity cohort. That does not make cross-trial comparisons perfect, but it does keep retatrutide in the conversation as the most potent weight-loss drug Lilly has in development. (investor.lilly.com) ### Why does the pain result matter so much? Because it turns abstract metabolic improvement into daily-life improvement. Knee osteoarthritis is one of the clearest places where excess weight becomes mechanical suffering — every step costs more. If a medicine takes off enough weight, the joint is carrying less load, inflammation may ease, and people can move more. That is basically the flywheel drugmakers want: less weight, less pain, more activity, then potentially even better long-term health. (investor.lilly.com) ### What is the catch? Topline data are not the same thing as a full paper. Lilly has not yet given the complete breakdown on adverse events, discontinuation rates, subgroup performance, or how durable the effect looks after treatment changes. And retatrutide still has to clear the rest of its phase 3 program. But the company already has seven more late-stage trials expected to complete in 2026, including studies in obesity, diabetes, sleep apnea, and other complications linked to excess weight. (investor.lilly.com) ### Where does this leave the obesity-drug race? It raises the ceiling again. The market used to ask whether these drugs could help people lose meaningful weight. Now the question is how close they can get to bariatric-surgery territory, and whether that weight loss translates into remission-style benefits across pain, diabetes, sleep apnea, and cardiovascular risk. Retatrutide is starting to look like Lilly’s strongest argument that the next phase of obesity treatment is about whole-body disease modification, not just smaller waistlines. (investor.lilly.com) ### Bottom line? TRIUMPH-4 matters because it says extreme weight loss may be clinically useful in a very concrete way — fewer pounds, less knee pain, better function. If the full data hold up, retatrutide will not just look powerful. It will look versatile. (investor.lilly.com)